Tony W. Ho

Family Medicine

232 S Woods Mill Rd
Chesterfield, MO 63017

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Scientific Advancements in Gene Therapies: Opportunities for Global Regulatory Convergence.

Scientific Advancements in Gene Therapies: Opportunities for Global Regulatory Convergence.

Journal: Biomedicines

Published: January 31, 2025

Regulatable C-X-C chemokine receptor type 4 in iPSC-derived NK cells improves bone marrow chemotaxis and targeting resident tumor.

Regulatable C-X-C chemokine receptor type 4 in iPSC-derived NK cells improves bone marrow chemotaxis and targeting resident tumor.

Journal: Trends in biotechnology

Published: December 16, 2024

High frequency CCR5 editing in human hematopoietic stem progenitor cells protects xenograft mice from HIV infection.

High frequency CCR5 editing in human hematopoietic stem progenitor cells protects xenograft mice from HIV infection.

Journal: Nature communications

Published: May 13, 2024

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. Reply.

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. Reply.

Journal: The New England journal of medicine

Published: June 09, 2021

Evaluation of Homology-Independent CRISPR-Cas9 Off-Target Assessment Methods.

Evaluation of Homology-Independent CRISPR-Cas9 Off-Target Assessment Methods.

Journal: The CRISPR journal

Published: December 21, 2020

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.

Journal: The New England journal of medicine

Published: December 07, 2020

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.

Journal: British journal of cancer

Published: April 23, 2018

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.

Journal: Oncotarget

Published: March 01, 2017

Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.

Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 18, 2016

Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease.

Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease.

Journal: Neurology

Published: September 29, 2016

Neurokinin B Receptor Antagonism in Women With Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial.

Neurokinin B Receptor Antagonism in Women With Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial.

Journal: The Journal of clinical endocrinology and metabolism

Published: July 27, 2016

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: December 22, 2015

Showing 1-12 of 24

Last Updated: 09/26/2026